Health economic aspects of dementia

Dementia 3Ed

Volumn , Issue , 2005, Pages 136-146

  Wimo, Anders ^a   Karlsson, Göran ^b   Winblad, Bengt ^c  

^a UMEÅ UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84937111574     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (134)

1. Allotey P, Reidpath D, Kouame A, Cummins R. (2003) The DALY, context and the determinants of the severity of disease: an exploratory comparison of paraplegia in Australia and Cameroon. Society of Scientific Medicine 57: 949-958
2. Almberg B, Grafstrom M, Krichbaum K, Winblad B. (2000) The interplay of institution and family caregiving: relations between patienthassles, nursing home hassles and caregivers' burnout. International Journal of Geriatric Psychiatry 15: 931-939
3. Beecham J, Cambridge P, Hallam A, Knapp M. (1993) The cost of Domus care. International Journal of Geriatric Psychiatry 8: 827-831
4. Berg L. (1988) Clinical dementia rating (CDR). Psychopharmacology Bulletin 24: 637-639
5. Bergner M, Bobbitt RA, Carter WB, Gilson BS. (1981) The Sickness Impact Profile: development and final revision of a health status measure. Medical Care 19: 787-805
6. Birks JS and Harvey R. (2003) Donepezil for dementia due to Alzheimer's disease. (Cochrane Review). Oxford: Software Update, Cochrane Library, Issue 3
7. Blau TH. (1977) Quality of life, social indicators and criteria of change. Professional Psychology 8: 464-473
8. Bowling A. (1995) Measuring Health. A review of quality of life measurement scales. Milton Keynes, Philadelphia, Open University Press
9. Brane G, Gottfries CG, Winblad B. (2001) The Gottfries-Brane-Steen scale: validity, reliability and application in anti-dementia drug trials. Dementia and Geriatric Cognitive Disorders 12: 1-14
10. Briggs AH and O'Brien BJ. (2001) The death of cost-minimization analysis? Health Economics 10: 179-184
11. Brod M, Stewart AL, Sands L, Walton P. (1999) Conceptualization and measurement of quality of life in dementia: the dementia quality of life instrument (DQoL). The Gerontologist 39: 25-35
12. Buxton MJ, Drummond MF, Van Hout BA et al. (1997) Modelling in economic evaluation: an unavoidable fact of life. Health Economics 6: 217-227
13. Caro JJ, Getsios D, Migliaccio-Walle K, Raggio G, Ward A. (2001) Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care. Neurology 57: 964-971
14. Caro JJ, Salas M, Ward A, Getsios D, Mehnert A. (2002) Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dementia and Geriatric Cognitive Disorders 14: 84-89
15. Cavallo MC and Fattore G. (1997) The economic and social burden of Alzheimer disease on families in the Lombardy region of Italy. Alzheimer Disease and Associated Disorders 11: 184-190
16. CCOHTA. (1997) Guidelines for economic evaluation of pharmaceuticals, 2nd edition. Ottawa, The Canadian Coordinating Office for Health Technology Assessment
17. Clegg A, Bryant J, Nicholson T et al. (2002) Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review. International Journal of Technological Assessment of Health Care 18: 497-507
18. Clipp EC and Moore MJ. (1995) Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. Clinical Pharmacology and Therapeutics 58: 228-236
19. Coucill W, Bryan S, Bentham P, Buckley A, Laight A. (2001) EQ-5D in patients with dementia: an investigation of inter-rater agreement. Medical Care 39: 760-771
20. CPMP. (1997) Note for guidance on medical products in the treatment of Alzheimer's disease. In: EMEA http://www.emea.eu.int/pdfs/human/ewp/055395en.pdf
21. Davis KL, Marin DB, Kane R et al. (1997) The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease. International Journal of Geriatric Psychiatry 12: 978-988
22. Deeken JF, Taylor KL, Mangan P, Yabroff KR, Ingham JM. (2003) Care for the caregivers: a review of self-report instruments developed to measure the burden, needs, and quality of life of informal caregivers. Journal of Pain and Symptom Management 26: 922-953
23. Dolan P. (2000) A note on QALYs versus HYEs. Health states versus health profiles. International Journal of Technological Assessment of Health Care 16: 1220-1224
24. Drummond MF. (2003) The use of health economic information by reimbursement authorities. Rheumatology (Oxford) 42 (Suppl. 3): 60-63
25. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. (1997) Methods for the Economic Evaluation of Health Care Programmes. Oxford, UK, Oxford University Press
26. Elstner K, Selai CE, Trimble MR, Robertson MM. (2001) Quality of Life (QoL) of patients with Gilles de la Tourette's syndrome. Acta Psychiatrica Scandinavica 103: 52-59
27. Ernst RL and Hay JW. (1994) The US economic and social costs of Alzheimer's disease revisited. American Journal of Public Health 84: 1261-1264
28. Ernst RL, Hay JW, Fenn C, Tinklenberg J, Yesavage JA. (1997) Cognitive function and the costs of Alzheimer disease. An exploratory study. Archives of Neurology 54: 687-693
29. Fenn P and Gray A. (1999) Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach. Pharmacoeconomics 16: 165-174
30. Ferris SH and Mittelman MS. (1996) Behavioral treatment of Alzheimer's disease. International Psychogeriatrics 8: 87-90
31. Fillit H, Gutterman EM, Lewis B. (1999) Donepezil use in managed Medicare: effect on health care costs and utilization. Clinical Therapeutics 21: 2173-2185
32. Folstein MF, Folstein SE, McHugh PR. (1975) 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12: 189-198
33. Garfield FB, Getsios D, Caro JJ, Wimo A, Winblad B. (2002) Assessment of Health Economics in Alzheimer's Disease (AHEAD). Treatment with Galantamine in Sweden. Pharmacoeconomics 20: 629-637
34. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. (2003) Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease Journal of American Geriatrics Society 51: 937-944
35. Getsios D, Caro JJ, Caro G, Ishak K. (2001) Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology 57: 972-978
36. Gray A. (2002) Health economics. In: N Qizilbash, L Schneider, H Chui, P Tariot, J Brodaty, J Kaye, T Erkinjuntti (eds), Evidence-Based Dementia Practice. Oxford, Blackwell Publishing, pp. 844-854
37. Grutzendler J and Morris JC. (2001) Cholinesterase inhibitors for Alzheimer's disease. Drugs 61: 41-52
38. Hauber AB, Gnanasakthy A, Mauskopf JA. (2000a) Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine. Clinical Therapeutics 22: 439-451
39. Hauber AB, Gnanasakthy A, Snyder EH, Bala MV, Richter A, Mauskopf JA. (2000b) Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine. Pharmacoeconomics 17: 351-360
40. Henke CJ and Burchmore MJ. (1997) The economic impact of the tacrine in the treatment of Alzheimer's disease. Clinical Therapeutics 19: 330-345
41. Hill S and McGettigan P. (1998) Drug authorities' policy on the assessment of drugs for dementia. In: A Wimo, G Karlsson, B Jönsson, B Winblad (eds), The Health Economics of Dementia. London, Wiley
42. Hill JW, Futterman R, Mastey V, Fillit H. (2002) The effect of donepezil therapy on health costs in a Medicare managed care plan. Management Care Interface 15: 63-70
43. Hux MJ, O'Brien BJ, Iskedjian M, Goeree R, Gagnon M, Gauthier S. (1998) Relation between severity of Alzheimer's disease and costs of caring. Canadian Medical Association Journal 159: 457-465
44. Ikeda S, Yamada Y, Ikegami N. (2002) Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. Dementia and Geriatric Cognitive Disorders 13: 33-39
45. Jansson W, Almberg B, Grafstrom M, Winblad B. (1998) The Circle Model-support for relatives of people with dementia. International Journal of Geriatric Psychiatry 13: 674-681
46. Johannesson M, Johansson PO, Jonsson B. (1992) Economic evaluation of drug therapy: a review of the contingent valuation method. Pharmacoeconomics 1: 325-337
47. Johannesson M, Jonsson B, Karlsson G. (1996) Outcome measurement in economic evaluation. Health Economics 5: 279-296
48. Jönsson L. (2003) Economic evaluation of treatments for Alzheimer's disease. Thesis. Stockholm: Karolinska Institutet
49. Jonsson L. (2003) Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease. Pharmacoeconomics 21: 1025-1037
50. Jonsson L, Lindgren P, Wimo A, Jonsson B, Winblad B. (1999a) The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clinical Therapeutics 21: 1230-1240
51. Jonsson L, Lindgren P, Wimo A, Jonsson B, Winblad B. (1999b) Costs of Mini-Mental State Examination-related cognitive impairment. Pharmacoeconomics 16: 409-416
52. Jonsson B, Jonsson L, Wimo A. (2000) In: M May and N Sartorius (eds), Dementia. WPA Series Evidence and Experience in Psychiatry. London, John Wiley and Sons, pp. 335-363
53. Karlsson G, Jonsson B, Wimo A, Winblad B. (1998) Methodological issues in health economics of dementia. In: A Wimo, G Karlsson, B Jönsson, B Winblad (eds), The Health Economics of Dementia. London, Wiley, pp. 161-169
54. Kerner DN, Patterson TL, Grant I, Kaplan RM. (1998) Validity of the Quality of Well-Being Scale for patients with Alzheimer's disease. Journal of Aging Health 10: 44-61
55. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. (1994) A 30-week randomized controlled trial of highdose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA 271: 985-991
56. Knopman D, Schneider L, Davis K et al. (1996) Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Tacrine Study Group. Neurology 47: 166-177
57. Koopmanschap MA. (1998) In: The Health Economics of Dementia. Wimo A, Karlsson G, Jonsson B, Winblad B (eds), London, John Wiley and Sons
58. Koopmanschap MA, Polder JJ, Meerding WJ, Bonneux L, van der Maas PJ. (1998) Costs of dementia in the Netherlands. In: A Wimo, G Karlsson, B Jönsson, B Winblad (eds), The Health Economics of Dementia. London, Wiley
59. Kronborg Andersen C, Sogaard J, Hansen E et al. (1999) The cost of dementia in Denmark: the Odense Study. Dementia and Geriatric Cognitive Disorders 10: 295-304
60. Lamb HM and Goa KL. (2001) Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics 19: 303-318
61. Langa KM, Chernew ME, Kabeto MU et al (2001) National estimates of the quantity and cost of informal caregiving for the elderly with dementia. Journal of General Internal Medicine 16: 770-778
62. Leber P. (1997) Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Disease and Associated Disorders 11 (Suppl. 5): S10-21; discussion S37-39
63. Leung GM, Yeung RY, Chi I, Chu LW. (2003) The economics of Alzheimer disease. Dementia and Geriatric Cognitive Disorders 15: 34-43
64. Lindgren B. (1981) Costs of Illness in Sweden 1964-1975. Lund, Liber
65. Logsdon RG, Gibbons LE, McCurry SM, Teri L. (2002) Assessing quality of life in older adults with cognitive impairment. Psychosomatic Medicine 64: 510-519
66. Lovestone S. (2002) Can we afford to develop treatments for dementia? Journal of Neurology, Neurosurgery, and Psychiatry 72: 685
67. Lubeck DP, Mazonson PD, Bowe T. (1994) Potential effect of tacrine on expenditures for Alzheimer's disease. Medical Interface 7: 130-138
68. Lyseng-Williamson KA and Plosker GL. (2002) Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics 20: 919-942
69. Lyseng-Williamson KA and Plosker GL. (2003) Spotlight on Galantamine in Alzheimer's Disease. Disease Management and Health Outcomes 11:125-128
70. Maas ML, Specht JP, Weiler K, Buckwalter KC, Turner B. (1998) Special care units for people with Alzheimer's disease. Only for the privileged few? Journal of Gerontological Nursing 24: 28-37
71. Max W. (1996) The cost of Alzheimer's disease. Will drug treatment ease the burden? Pharmacoeconomics 9: 5-10
72. Max W, Webber P, Fox P. (1995) Alzheimer's disease. The unpaid burden of caring. Journal of Aging Health 7: 179-199
73. Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O'Brien JA, Papadopoulos G. (2003) Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clinical Therapeutics 25: 1806-1825
74. Mohide EA, Torrance GW, Streiner DL, Pringle DM, Gilbert R. (1988) Measuring the wellbeing of family caregivers using the time tradeoff technique. Journal of Clinical Epidemiology 41: 475-482
75. Moore MJ, Zhu CW, Clipp EC. (2001) Informal costs of dementia care: estimates from the National Longitudinal Caregiver Study. Journal of Gerontology, B Psychological Sciences and Social Sciences 56:S219-228
76. Neumann PJ, Hermann RC, Kuntz KM et al. (1999) Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 52: 1138-1145
77. Neumann PJ, Sandberg EA, Araki SS, Kuntz KM, Feeny D, Weinstein MC. (2000) A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. Medical Decision Making 20: 413-422
78. NICE. (2001) Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease. Technology Appraisal Guidance No.19. London, National Institute for Clinical Excellence, pp. 5-6
79. O'Brien BJ, Goeree R, Hux M et al. (1999) Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. Journal of American Geriatrics Society 47: 570-578
80. O'Shea E and O'Reilly S. (2000) The economic and social cost of dementia in Ireland. International Journal of Geriatric Psychiatry 15: 208-218
81. OECD. PPP http://www.oecd.org/std/ppp/pps
82. OECD. (1996) Caring for Frail Elderly People - Policies in Evolution. Social Policy Studies No. 19. Paris, Organization for Economic Development
83. Olin J and Schneider L. (2003) Galantamine for Alzheimer's disease. Cochrane Review. Oxford, Software Update Cochrane Library, Issue 2
84. Ostbye T and Crosse E. (1994) Net economic costs of dementia in Canada. Canadian Medical Association Journal 151: 1457-1464
85. Reisberg B, Ferris SH, de Leon MJ, Crook T. (1988) Global Deterioration Scale (GDS). Psychopharmacological Bulletin 24: 661-663
86. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. (2003) Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine 348: 1333-1341
87. Rice DP, Hodgson TA, Kopstein AN. (1985) The economic costs of illness: a replication and update. Health Review 7: 61-80
88. Rice DP, Fox PJ, Max W et al. (1993) The economic burden of Alzheimer's disease care. Health Affairs (Project Hope) 12: 164-176
89. Rosen WG, Mohs RC, Davis KL. (1984) A new rating scale for Alzheimer's disease, American Journal of Psychiatry 141: 1356-1364
90. Salek SS, Walker MD, Bayer AJ. (1998) A review of quality of life in Alzheimer's disease. Part 2: Issues in assessing drug effects. Pharmacoeconomics 14: 613-627
91. Sano M, Ernesto C, Thomas RG et al. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New England Journal of Medicine 336: 1216-1222
92. Schneider L. (1998) In: Health Economics of Dementia. Wimo A, Jonsson B, Karlsson G, Winblad B (eds), London, John Wiley and Sons. pp. 451-464
93. Schneider LS, Olin JT, Lyness SA, Chui HC. (1997) Eligibility of Alzheimer's disease clinic patients for clinical trials. Journal of American Geriatrics Society 45: 923-928
94. Schulenberg J and Schulenberg I. (1998) Cost of treatment and cost of care for Alzheimer's disease in Germany. In: A Wimo, G Karlsson, B Jönsson, B Winblad (eds), The Health Economics of Dementia. London, Wiley
95. Schulz R and Beach SR. (1999) Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA 282: 2215-2219
96. Selai C, Vaughan A, Harvey RJ, Logsdon R. (2001) Using the QoL-AD in the UK, International Journal of Geriatric Psychiatry 16: 537-538
97. Selai CE, Elstner K, Trimble MR. (2000) Quality of life pre and post epilepsy surgery. Epilepsy Research 38: 67-74
98. Shukla VK, Otten N, Coyle D. (2000) Drug treatments for Alzheimer's Disease III. a review of published pharmacoeconomic evaluations. Report No. 11. Ottawa, Canadian Coordinating Office for Health Technology Assessment (CCOHTA), p. 37
99. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. (1997) Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on Cost Effectiveness in Health and Medicine. Pharmacoeconomics 11:159-168
100. Small GW, Donohue JA, Brooks RL. (1998) An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clinical Therapeutics 20: 838-850
101. Smith KA and Shah A. (1995) The prevalence and costs of psychiatric disorders and learning disabilities. British Journal of Psychiatry 166: 9-18
102. Sonnenberg FA and Leventhal EA. (1998) Modeling disease progression with Markov models. In: A Wimo, G Karlsson, B Jönsson, B Winblad (eds), The Health Economics of Dementia. London, Wiley, pp. 171-196
103. Spilker B. (1996) Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, Lippincott-Raven Publishers
104. Stewart A and Brod M. (1996) In: B Spilker (ed.), Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, Lippincott-Raven Publishers, pp. 819-830
105. Stewart A, Phillips R, Dempsey G. (1998) Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. International Journal of Geriatric Psychiatry 13: 445-453
106. Stommel M, Collins CE, Given BA. (1994) The costs of family contributions to the care of persons with dementia. The Gerontologist 34: 199-205
107. Torrance G. (1996) In: B Spilker (ed.), Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia, Lippincott-Raven Publishers, pp. 1105-1121
108. Torrance GW. (1997) Preferences for health outcomes and cost-utility analysis. American Journal of Management Care 3 (Suppl.): S8-20
109. Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. (1996) Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Medical Care 34: 702-722
110. Tsuchiya A, Dolan P, Shaw R. (2003) Measuring people's preferences regarding ageism in health: some methodological issues and some fresh evidence, Society of Scientific Medicine 57: 687-696
111. Walker MD, Salek SS, Bayer AJ. (1998) A review of quality of life in Alzheimer's disease. Part 1: Issues in assessing disease impact. Pharmacoeconomics 14: 499-530
112. Ward A, Caro JJ, Getsios D, Ishak K, O'Brien J, Bullock R. (2003) Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. International Journal of Geriatric Psychiatry 18: 740-747
113. Ware JE Jr and Sherbourne CD. (1992) The MOS 36-item short-form health survey (SF-36) I. Conceptual framework and item selection. Medical Care 30: 473-483
114. Weinstein MC and Fineberg HV. (1980) Clinical Decision Analysis. Philadelphia, WB Saunders
115. Wimo A and Winblad B. (2002) Pharmacoeconomics of dementia: impact of cholinesterase inhibitors. In: S Gauthier S and J Cummings (eds), Alzheimer's Disease and Related Disorders Annual 2002. London, Martin Dunitz
116. Wimo A and Winblad B. (2003a) Pharmacoeconomics of mild cognitive impairment. Acta Neurologica Scandinavica 179 (Suppl.): 94-99
117. Wimo A and Winblad B. (2003b) Resource utilisation in dementia: RUD Lite. Brain Aging 3: 48-59
118. Wimo A, Mattson B, Krakau I, Eriksson T, Nelvig A, Karlsson G. (1995) Cost-utility analysis of group living in dementia care. International Journal of Technological Assessment of Health Care 11: 49-65
119. Wimo A, Karlsson G, Nordberg A, Winblad B. (1997a) Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alzheimer Disease and Associated Disorders 11: 191-200
120. Wimo A, Karlsson G, Sandman PO, Corder L, Winblad B. (1997b) Cost of illness due to dementia in Sweden. International Journal of Geriatric Psychiatry 12: 857-861
121. Wimo A, Jonsson B, Karlsson G, Winblad BE. (1998a) The Health Economics of Dementia. London, John Wiley and Sons
122. Wimo A, Wetterholm AL, Mastey V, Winblad B. (1998b) Evaluation of the resource utilization and caregiver time in Anti-dementia drug trials - a quantitative battery. In: A Wimo, G Karlsson, B Jönsson, B Winblad (eds), The Health Economics of Dementia. London, Wiley, pp. 465-499
123. Wimo A, Witthaus E, Rother M, Winblad B. (1998c) Economic impact of introducing propentofylline for the treatment of dementia in Sweden. Clinical Therapeutics 20: 552-566; discussion 550-551
124. Wimo A, Johansson L, von Strauss E, Nordberg G. (1999a) Formal and informal home care to Swedish demented patients, an application of RUD (Resource Utilization in Dementia) (abstract). International Psychogeriatrics 11 (Suppl. 1): 197
125. Wimo A, Winblad B, Grafstrom M. (1999b) The social consequences for families with Alzheimer's disease patients: potential impact of new drug treatment. International Journal of Geriatric Psychiatry 14: 338-347
126. Wimo A, Nordberg G, Jansson W, Grafstrom M. (2000) Assessment of informal services to demented people with the RUD instrument. International Journal of Geriatric Psychiatry 15: 969-971
127. Wimo A, von Strauss E, Nordberg G, Sassi F, Johansson L. (2002) Time spent on informal and formal care giving for persons with dementia in Sweden. Health Policy 61: 255-268
128. Wimo A, Winblad B, Engedal K et al. (2003a) An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dementia and Geriatric Cognitive Disorders 15: 44-54
129. Wimo A, Winblad B, Stoffler A, Wirth Y, Mobius HJ. (2003b) Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 21: 327-40
130. Wimo A, Winblad B, Stöffler A, Wirth Y, Möbius HJ. (2003c) Resource utilization and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 21: 327-340
131. Winblad B, Hill S, Beermann B, Post SG, Wimo A. (1997) Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Disease and Associated Disorders 11: 39-45
132. Winblad B, Wimo A, Mobius HJ, Fox JM, Fratiglioni L. (1999) Severe dementia: a common condition entailing high costs at individual and societal levels. International Journal of Geriatric Psychiatry 14: 911-914
133. Wolfson C, Oremus M, Shukla V et al. (2002) Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clinical Therapeutics 24: 862-886; discussion 837
134. Zarit SH, Reever KE, Bach-Peterson J. (1980) Relatives of the impaired elderly: correlates of feelings of burden. The Gerontologist 20: 649-655